Strategic CDMO RoslinCT is a leading global CDMO specializing in Advanced Cell Therapies with robust cGMP manufacturing in Edinburgh and Hopkinton, indicating strong contract manufacturing capabilities and potential for expanded partnerships in autologous and allogeneic cell therapies.

Capable scale With 22 purpose-built cGMP processing suites and ongoing facility expansion in Hopkinton to support both autologous and allogeneic products, RoslinCT presents opportunities for capacity-led collaborations and scale-up programs.

Innovative edge Pioneering work including clinical-grade pluripotent stem cells and CRISPR-edited cell therapy development positions RoslinCT as a partner for end-to-end development to commercialization, appealing to sponsors seeking cutting-edge gene-edited therapies.

Strategic partnerships Recent collaborations with Vertex and BlueRock Therapeutics, along with leadership appointments, signal a growth-focused ecosystem that enhances credibility for joint development programs and potential co-development or licensing discussions.

Growth signals Revenue in the mid-range ($50M-$100M) with recent funding activities and significant hiring/board expansion suggest capacity for increased outsourcing demand and new CDMO engagements, including iPSC line development and gene editing services.